News for hackers. Stuff that matters.
Re:Compass Pathways' Phase IIb psilocybin trial shows reduce... by PragmaticPulp on Tuesday November 09, 2021 @07:03PM (#29169282)
The trial tested psilocybin combined with therapy. This isn’t equivalent to ad-hoc self treatment with mushrooms.

They noticed a response to psilocybin+therapy in about 20-25% of patients depending on the criteria for “sustained response”:

> The protocol-defined sustained response* up to week 12 was double, with 20.3% of patients in the 25mg group

It’s also notable that about 5% of the psilocybin receivers experienced severe adverse events including suicidal ideation:

> There were 12 patients who reported treatment-emergent serious adverse events (TESAEs). These TESAEs included suicidal behaviour, intentional self-injury, and suicidal ideation

Re:Compass Pathways' Phase IIb psilocybin trial shows reduce... by JohnJamesRambo on Tuesday November 09, 2021 @07:28PM (#29169507)
This sounds pretty crappy right? If I'm understanding the numbers, 25% response is about like what we get with a placebo in most studies if my memory is correct.

It sounds like they were tripping balls on 25 mg, so this is definitely in active placebo range.

From my memory:

Placebo is about 25%.

Antidepressants about 35% response rate.

Active placebo of something like atropine which makes you feel weird but isn't an antidepressant has about a 35% response rate.

https://blogs.scientificamerican.com/cross-check/are-antidep...

Re:Compass Pathways' Phase IIb psilocybin trial shows reduce... by drooby on Tuesday November 09, 2021 @09:27PM (#29170395)
I’m not sure if it makes a difference, but this study was conducted on _treatment resistant_ patients.